Manuscripts
Showing 1595 manuscripts.
Heterogeneity of T Cell Responses to Pandemic pH1n1 Monovalent Vaccine in HIV-Infected Pregnant Women
Citation
Adriana Weinberg , Petronella Muresan, Kelly Richardson, Terence Fenton, Teresa Dominguez, Anthony Bloom, D Heather Watts, Mark J Abzug, Sharon A Nachman, Myron J Levin for the P1086 study team. Heterogeneity of T Cell Responses to Pandemic pH1n1 Monovalent Vaccine in HIV-Infected Pregnant Women. AIDS Research and Human Retroviruses. 2015 Nov 14; 31(11):1170-7. PMID: 26322930; PMCID: PMC4651022.Year
2015
Journal
AIDS Research and Human Retroviruses
Study
P1086
Characterization of functional antibody and memory B-cell responses to pH1N1 monovalent vaccine in HIV-infected children and youth
Citation
DJ Curtis, P Muresan, S Nachman, T Fenton, KM Richardson, T Dominguez, PM Flynn, SA Spector, CK Cunningham, A Bloom, A Weinberg. Characterization of functional antibody and memory B-cell responses to pH1N1 monovalent vaccine in HIV-infected children and youth. PLoS One. 2015 Mar 18; 3:e0118567. PMID: 25785995; PMCID: PMC4364897.Year
2015
Journal
PLoS One
Study
P1088
Cost-effectiveness of first-line antiretroviral therapy for
HIV-infected African children less than three years of age
Citation
AL Ciaranello, K Doherty, M Penazzato, JC Lindsey, L Harrison, K Kelly, RP Walensky, S Essajee, E Losina, L Muhe, K Wools-Kaloustian, S Ayaya, MC Weinstein, P Palumbo, KA Freedberg. Cost-effectiveness of first-line antiretroviral therapy for HIV-infected African children less than three years of age. AIDS. 2015 Jun 19; 29(10):1247-1259. PMID: 25870982; PMCID: PMC4536981.Year
2015
Journal
AIDS
Study
P1060
Safety, Pharmacokinetics and Efficacy of Dolutegravir in Treatment-Experienced HIV-1 Infected Adolescents: 48-Week Results from IMPAACT P1093
Citation
Rolando M. Viani, Carmelita Alvero, Terry Fenton, Edward P. Acosta, Rohan Hazra, Ellen O’Gara, Debra Steimers, Sherene Min, Andrew Wiznia on behalf of the P1093 study team. Safety, Pharmacokinetics and Efficacy of Dolutegravir in Treatment-Experienced HIV-1 Infected Adolescents: 48-Week Results from IMPAACT P1093. Pediatric Infectious Disease Journal. 2015 Nov 11; 34(11):1207-1213. PMID: 26244832; PMCID: PMC4604048.Year
2015
Journal
Pediatric Infectious Disease Journal
Study
P1093
Effect of Cytomegalovirus Co-infection on Normalization of Selected T-cell Subsets in Children with Perinatally Acquired HIV Infection Treated with Combination Antiretroviral Therapy
Citation
Suad Kapetanovic, Lisa Aaron, Grace Montepiedra, Patricia Anthony, Kasalyn Thuvamontolrat, Savita Pahwa, Sandra Burchett, Adriana Weinberg, Andrea Kovacs for the Pediatric AIDS Clinical Trials Group. Effect of Cytomegalovirus Co-infection on Normalization of Selected T-cell Subsets in Children with Perinatally Acquired HIV Infection Treated with Combination Antiretroviral Therapy. PLoS One. 2015 Mar 20; 10(3):e0120474. PMID: 25794163; PMCID: PMC4368806.Year
2015
Journal
PLoS One
Immunologic and Virologic Outcomes of Treatment Switch Strategies After Combination Antiretroviral Treatment Failure Among Perinatally HIV-infected Children and Adolescents in the United States
Citation
Lee Fairlie, Brad Karalius, Kunjal Patel, Russell B. Van Dyke, Rohan Hazra, Miguel A. Hernán, George K Siberry, George R. Seage III, Allison Agwu, Hermann Mendez, Andrew Wiznia for PHACS and IMPAACT. Immunologic and Virologic Outcomes of Treatment Switch Strategies After Combination Antiretroviral Treatment Failure Among Perinatally HIV-infected Children and Adolescents in the United States. AIDS. 2015 Jul 24; 29(16):2109-19. PMID: 26182197.Year
2015
Journal
AIDS
Psychiatric condition symptoms and antiretroviral non-adherence in US youth with perinatal HIV infection: A longitudinal study
Citation
Deborah Kacanek, Konstantia Angelidou, Paige L. Williams, Miriam Chernoff, Kenneth D. Gadow, Sharon Nachman for IMPAACT P1055 Study Team. Psychiatric condition symptoms and antiretroviral non-adherence in US youth with perinatal HIV infection: A longitudinal study. AIDS. 2015 Jun 19; 29(10):1227-1237. PMID: 26035322.Year
2015
Journal
AIDS
Study
P1055
HIV-1 Drug Resistance and Second-line Treatment in Children Randomized to Switch at Low versus Higher RNA Thresholds
Citation
Linda Harrison, Ann Melvin , Susan Fiscus , Yacine Saidi , Eleni Nastouli , Lynda Harper , Alexandra Compagnucci , Abdel Babiker , Ross McKinney , Diana Gibb , Gareth Tudor-Williams , the PENPACT-1 (PENTA 9/PACTG 390) Study Team. HIV-1 Drug Resistance and Second-line Treatment in Children Randomized to Switch at Low versus Higher RNA Thresholds. Journal of Acquired Immune Deficiency Syndromes. 2015 Sep 01; 70(1):42-53. PMID: 26322666; PMCID: PMC4556171.Year
2015
Journal
Journal of Acquired Immune Deficiency Syndromes
Cell-Associated HIV-1 DNA and RNA Decay Dynamics during Early Combination Antiretroviral Therapy in HIV-1-Infected Infants
Citation
Priyanka Uprety, Ellen G. Chadwick, Kaitlin Rainwater-Lovett, Carrie Ziemniak, Katherine Luzuriaga, Edmund V. Capparelli, Gayane Yenokyan, Deborah Persaud. Cell-Associated HIV-1 DNA and RNA Decay Dynamics during Early Combination Antiretroviral Therapy in HIV-1-Infected Infants. Clinical Infectious Diseases. 2015 Dec 13; 15(61(12)):1862-70. PMID: 26270687; PMCID: PMC4657533.Year
2015
Journal
Clinical Infectious Diseases
Study
P1030
Long-term safety and efficacy of atazanavir-based therapy in HIV-infected infants, children and adolescents: the Pediatric AIDS Clinical Trials Group Protocol 1020A.
Citation
RM Rutsein, P Samson, T Fenton, CV Fletcher, JJ Kiser, Mofenson LM, E Smith, B Graham, M Mathew, G Aldrovani, PACTG 1020A Study Team. Long-term safety and efficacy of atazanavir-based therapy in HIV-infected infants, children and adolescents: the Pediatric AIDS Clinical Trials Group Protocol 1020A. Pediatric Infectious Disease Journal. 2015 Feb 02; 34(2):162-167. PMID: 25232777; PMCID: PMC4355059.Year
2015
Journal
Pediatric Infectious Disease Journal
Study
P1020A